A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

NCT07325526 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Cirrhosis

Interventions

DRUG: BI 3802876
DRUG: Placebo

Sponsor

Boehringer Ingelheim